1. MARKETS
  2. SECTOR : CHEMICALS & PETROCHEMICALS
  3. INDUSTRY : SPECIALTY CHEMICALS
  4. JUBILANT INGREVIA LTD.
Jubilant Ingrevia Ltd.
NSE: JUBLINGREA | BSE: 543271

Jubilant Ingrevia Live Share Price Today, Share Analysis and Chart

Falling Comet
aboutJubilant Ingrevia Limited is a multi-focus integrated life science products and innovative solutions provider, operating as a core entity within the Jubilant Bhartia Group. The company maintains a leadership position in the global specialty chemicals... Read More
Export DemandEBITDA per Kg
Ask AI about Jubilant Ingrevia
558.40-9.45(-1.66%)

Near 52W Low of ₹537.30

732.7K
NSE+BSE Volume

High vol. this week

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
32.3 / 100
Falling CometThese stocks have good quality scores. However, their weak technicals make them more bearishView SimilarEmbed DVM
Analyst Price Target
-

21

S

8

W

5

O

2

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

14Positive9Negative

Pass in checklist60.9%

045
55
100

PE Valuation Check

Right Now
Undervalued
40.3%
1 Year Forward
Undervalued
70.6%
INSIGHTJubilant Ingrevia is undervalued at both current PE and future earnings estimates.

Jubilant Ingrevia Stock Price Analysis

Day Price Range

-1.7% 1 Day return
558.4 (LTP)
544568.4
LowHigh

Week Price Range

-7.2% 1 Week return
558.4 (LTP)
544658.4
LowHigh

Month Price Range

-12.6% 1 Month return
558.4 (LTP)
544677.4
LowHigh

52 Week Price Range

-19.9% 1 Year return
558.4 (LTP)
537.3795
LowHigh
View full Price History/Seasonality

Jubilant Ingrevia Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Jubilant Ingrevia's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
17.5
AVG. ESTIMATE
26.7
LOW ESTIMATE
25.1
HIGH ESTIMATE
27.9
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 52.2% in FY27

Consensus Recommendation

6 ANALYST Recommendations
STRONG BUY

The consensus recommendation from 6 analysts for Jubilant Ingrevia is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Jubilant Ingrevia Technical Analysis

Jubilant Ingrevia EMA & SMA

Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
5 Day583.1
10 Day597.6
12 Day601.5
20 Day613.3
26 Day620.5
50 Day641.6
100 Day659.0
200 Day668.1

Jubilant Ingrevia Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202651.4%
Week44.8%
Month46.4%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Jubilant Ingrevia Resistance and Support

556.93
Pivot
First Resistance569.9
Second Resistance581.3
Third Resistance594.3
First Support545.5
Second Support532.5
Third Support521.1
Day RSI32.1
Day MACD-19
Day MFI39.7
Day MACD Signal Line-14.5

Jubilant Ingrevia Beta

1 Month0.2
1 Year1.2
3 Month0.7
3 Year1.0

Jubilant Ingrevia Price Change Analysis

↓-12.6%
Over 1 Month
LowHigh
544677.4
↓-23.3%
Over 3 Months
LowHigh
544769.7
↓-20.5%
Over 6 Months
LowHigh
544795
↓-19.9%
Over 1 Year
LowHigh
537.3795
All Technicals →

Jubilant Ingrevia Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Hsb Trustee Company Pl & Hs Trustee Company PlPromoter30,257,47519 %
Rekha JhunjhunwalaPublic4,735,5003.0 %
Dsp Small Cap FundDii10,147,5576.4 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Jubilant Ingrevia Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
EAST BRIDGE CAPITAL MASTER FUND I LIMITEDBulkPurchase28 Oct 2026601.75921,668BSE
JUBILANT ENPRO PRIVATE LIMITEDBlockSell13 Jun 20256762,827,071NSE
NIKITA RESOURCES PRIVATE LIMITEDBlockSell13 Jun 20256763,414,540NSE
SHYAM SUNDER BHARTIA FAMILY TRUSTBlockSell13 Jun 20256763,623,460NSE
SOCIETE GENERALEBlockPurchase13 Jun 2025676380,000NSE
AXIS MUTUAL FUNDBlockPurchase13 Jun 20256761,900,000NSE
BANDHAN MUTUAL FUNDBlockPurchase13 Jun 2025676400,000NSE
HDFC MUTUAL FUNDBlockPurchase13 Jun 20256761,970,000NSE
ICICI PRUDENTIAL LIFE INSURANCE COMPANY LIMITEDBlockPurchase13 Jun 2025676360,000NSE
MORGAN STANLEY ASIA SINGAPORE PTEBlockPurchase13 Jun 2025676390,000NSE
All deals
All insider trades

Jubilant Ingrevia Corporate Actions

Jubilant Ingrevia Dividend history and yield

Jubilant Ingrevia dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Jubilant Ingrevia dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
124 Jul 2026
2.5FINAL24 Jul 2026Equity Share
210 Feb 2026
2.5INTERIM10 Feb 2026Equity Share
325 Jul 2025
2.5FINAL25 Jul 2025Equity Share
403 Feb 2025
2.5INTERIM03 Feb 2025Equity Share
502 Aug 2024
2.5FINAL02 Aug 2024Equity Share

Jubilant Ingrevia Board Meetings

Jubilant Ingrevia past and upcoming board meetings.

#Ex-Date
PurposeNotes
127 Oct 2026
Quarterly Results-
222 Jul 2026
Quarterly Results-
326 May 2026
Audited Results & Final Dividend-
404 Feb 2026
Quarterly Results-
527 Oct 2025
Quarterly Results-
All Corporate Actions

Jubilant Ingrevia Research Reports

Jubilant Ingrevia research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
127 Oct 2026Anand Rathi900632.35Buy42.33%-11.69%pdf
223 Sep 2026Axis Direct705635.35Buy10.96%-12.11%pdf
323 Aug 2026Axis Direct835708.2Buy17.9%-21.15%pdf
423 Jul 2026Anand Rathi
Target
980745.05Buy31.53%-25.05%pdf
523 Jul 2026Axis Direct
Target
835725.55Buy15.09%-23.04%pdf
All Reports of Jubilant

Jubilant Ingrevia Corporate Filings

Jubilant Ingrevia BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
28 Oct 2026
Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of results for quarter and half year ended September 30, 2026
PDF
27 Oct 2026
Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulations 30 of the SEBI Listing Regulations, we wish to inform that audio recording of investors' Conference Call for un-audited financial results for the quarter and half year ended September 30, 2026, held on Tuesday, October 27, 2026 has been uploaded on the Company's website.
PDF
27 Oct 2026
Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release & Investor Presentation
PDF
27 Oct 2026
Q2FY27 Quarterly Result Announced for Jubilant Ingrevia Ltd.
Specialty Chemicals company Jubilant Ingrevia announced Q2FY27 results Consolidated Financial Highlights: Revenue from operations recorded at Rs 1,39,423 lakh in Q2FY27, growing by 7.23% QoQ from Rs 1,30,027 lakh in Q1FY27, up 24.40% YoY from Rs 1,12,073 lakh in Q2FY26, and stood at Rs 2,69,450 lakh for H1FY27, an increase of 24.82% YoY from Rs 2,15,868 lakh in H1FY26. Total income reached Rs 1,40,326 lakh in Q2FY27, expanding by 7.08% QoQ compared to Rs 1,31,049 lakh in Q1FY27, higher by 24.01% YoY versus Rs 1,13,154 lakh in Q2FY26, and aggregated Rs 2,71,375 lakh for H1FY27, rising by 24.44% YoY from Rs 2,18,071 lakh in H1FY26. Profit before tax (PBT) recorded Rs 1,4,798 lakh in Q2FY27, increasing by 5.06% QoQ over Rs 1,4,086 lakh in Q1FY27, up 59.36% YoY relative to Rs 9,286 lakh in Q2FY26, and posted Rs 28,884 lakh for H1FY27, showing a YoY growth of 49.95% over Rs 19,263 lakh in H1FY26. Net profit after tax (PAT) stood at Rs 11,143 lakh in Q2FY27, expanding by 5.30% QoQ against Rs 10,582 lakh in Q1FY27, up 60.40% YoY against Rs 6,947 lakh in Q2FY26, and posted Rs 21,725 lakh for H1FY27, climbing by 50.27% YoY against Rs 14,457 lakh in H1FY26. Earnings per equity share (EPS - Basic) reached Rs 7.07 in Q2FY27, growing 5.52% QoQ from Rs 6.70 in Q1FY27, up 60.68% YoY against Rs 4.40 in Q2FY26, and was recorded at Rs 13.77 for H1FY27, showcasing a YoY growth of 50.49% over Rs 9.15 in H1FY26. Standalone Financial Highlights: Revenue from operations recorded at Rs 1,22,595 lakh in Q2FY27, descending by 2.13% QoQ from Rs 1,25,265 lakh in Q1FY27, expanding by 16.29% YoY from Rs 1,05,418 lakh in Q2FY26, and stood at Rs 2,47,860 lakh for H1FY27, tracking a YoY increase of 22.26% over Rs 2,02,726 lakh in H1FY26. Total income reached Rs 1,23,572 lakh in Q2FY27, down 2.18% QoQ against Rs 1,26,322 lakh in Q1FY27, but up 16.03% YoY against Rs 1,06,509 lakh in Q2FY26, and aggregated Rs 2,49,894 lakh for H1FY27, indicating a YoY expansion of 21.94% from Rs 2,04,927 lakh in H1FY26. Profit before tax (PBT) reached Rs 9,473 lakh in Q2FY27, down 44.15% QoQ from Rs 16,961 lakh in Q1FY27, but up 59.32% YoY over Rs 5,946 lakh in Q2FY26, and totaled Rs 26,434 lakh for H1FY27, showcasing a YoY growth of 97.45% from Rs 13,888 lakh in H1FY26. Net profit after tax (PAT) stood at Rs 7,040 lakh in Q2FY27, declining 44.22% QoQ from Rs 12,622 lakh in Q1FY27, but scaling up 59.89% YoY from Rs 4,403 lakh in Q2FY26, and recorded Rs 19,662 lakh for H1FY27, a YoY expansion of 90.82% over Rs 10,304 lakh in H1FY26. Earnings per equity share (EPS - Basic) posted at Rs 4.42 in Q2FY27, decreasing 44.19% QoQ from Rs 7.92 in Q1FY27, up 59.57% YoY over Rs 2.77 in Q2FY26, and stood at Rs 12.34 for H1FY27, showcasing a YoY growth of 90.73% against Rs 6.47 in H1FY26. Segment-Wise Performance: Speciality Chemicals: Rs 68,116 lakh in Q2FY27 (up 6.93% QoQ vs Rs 63,700 lakh; up 27.21% YoY vs Rs 53,544 lakh); Rs 1,31,816 lakh in H1FY27 (up 22.92% YoY vs Rs 1,07,241 lakh). Nutrition & Health Solutions: Rs 27,070 lakh in Q2FY27 (up 11.02% QoQ vs Rs 24,382 lakh; up 49.88% YoY vs Rs 18,061 lakh); Rs 5,1452 lakh in H1FY27 (up 43.13% YoY vs Rs 35,948 lakh). Chemical Intermediates: Rs 56,519 lakh in Q2FY27 (up 7.62% QoQ vs Rs 52,517 lakh; up 23.66% YoY vs Rs 45,705 lakh); Rs 1,09,036 lakh in H1FY27 (up 30.01% YoY vs Rs 83,870 lakh). Result PDF
PDF
27 Oct 2026
Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Change in Management
Resignation of SMP
PDF
VIEW ALL

Jubilant Ingrevia DocumentsAsk MarketMind AI

Jubilant Ingrevia Earnings Call

Jubilant Ingrevia earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
27 Oct 2026Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
27 Jul 2026Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
23 Jul 2026Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
29 May 2026Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
29 May 2026Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
view all

Jubilant Ingrevia Annual Reports

Jubilant Ingrevia financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Jubilant Ingrevia Credit Ratings

Jubilant Ingrevia credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
10 Aug 2026crisil ratingsJubilant Ingrevia LimitedJubilant Ingrevia Limited:Rating reaffirmed at 'Crisil A1+'Link
01 Dec 2025india ratingsIndia Ratings Affirms Jubilant Ingrevia’s Bank Loans at ‘IND AA+’/Stable; Withdraws CP rating Link
11 Aug 2025crisil ratingsJubilant Ingrevia LimitedJubilant Ingrevia Limited:Rating reaffirmed at 'Crisil A1+'Link
11 Aug 2024crisil ratingsJubilant Ingrevia LimitedJubilant Ingrevia Limited:Rating reaffirmed at 'CRISIL A1+'Link
01 Feb 2024india ratingsIndia Ratings Affirms Jubilant Ingrevia’s Bank Facilities at ‘IND AA+’/Stable; Rates New Term LoanLink

Jubilant Ingrevia Investor Presentations

Jubilant Ingrevia investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
27 Oct 2026Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseLink
27 Oct 2026Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
22 Jul 2026Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
26 May 2026Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
05 Feb 2026Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Jubilant Ingrevia - Company Profile

Jubilant Ingrevia Management Structure

Jubilant Ingrevia management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Deepak JainExecutive Director,Managing Director,Chief Executive Officer1445.8Mar 26
Vijay Kumar SrivastavaExecutive Director,Whole Time Director,Chief of Operations332.5Mar 26
Mr. Varun GuptaPresident,Chief Financial Officer-Mar 26
Mr. Ambrish DixitHead(Chemicals.)-Mar 26
Ms. Vinita KoulExecutive Vice President,Head(Human Resources)-Mar 26
Mr. Birajeev SinghSenior Vice President,Head(Supply Chain.)-Mar 26
Deepanjali GulatiCompany Secretary,Compliance Officer-Mar 26

Jubilant Ingrevia Board of Directors

Jubilant Ingrevia Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Hari S BhartiaCo-Chairman / Non Independent ED / WTD1837.8Mar 26
Deepak JainManaging Director & CEO1445.8Mar 26
Vijay Kumar SrivastavaED / WTD / Chief of Operations332.5Mar 26
Pradeep BanerjeeIndependent Non Exe. Director30Mar 26
SIRAJ AZMAT CHAUDHRYIndependent Non Exe. Director29.25Mar 26
Ameeta ChatterjeeIndependent Non Exe. Director29Mar 26
S K RoongtaIndependent Non Exe. Director27.75Mar 26
Arun Seth.Independent Non Exe. Director26.75Mar 26
Sudha PillaiIndependent Non Exe. Director26Mar 26
Shyam S BhartiaChairman & Non Executive Dir.22Mar 26
Priyavrat BhartiaNon Executive Director15Mar 26
AASHTI BHARTIANon Executive Director10Mar 26
Deepanjali GulatiCompany Sec. & Compli. Officer-Mar 26
Website: www.jubilantingrevia.com

About the company - Business Profile

Jubilant Ingrevia Limited is a multi-focus integrated life science products and innovative solutions provider, operating as a core entity within the Jubilant Bhartia Group. The company maintains a leadership position in the global specialty chemicals and nutrition markets, offering a broad portfolio of ingredients used in the pharmaceutical, agrochemical, nutrition, and consumer industrial sectors. Its business model is built on deep vertical integration, primarily centered around its core Pyridine and Diketene chemistry value chains.

Key Points

  • Corporate Profile and Operations: Headquartered in Noida, Uttar Pradesh, Jubilant Ingrevia was formed following the demerger of the Life Science Ingredients business from Jubilant Life Sciences Limited in early 2021. The company operates 50 plants across five manufacturing complexes in India located at Gajraula, Bharuch, Nira, Samlaya, and Savli. It supports its manufacturing with three R&D centers and a workforce of over 2,300 professionals, including 150 scientists.
  • Market Position: The company is the global leader (#1) in the Pyridine and Picolines merchant market and is one of the largest manufacturers of Vitamin B3 (Niacinamide and Niacin) globally. It also holds a leading position in the merchant market for Acetic Anhydride in India.
  • Business Segments and Revenue: In FY 2025, the company reported consolidated revenue of ₹41,776 million. The revenue is divided across three primary segments:
    • Specialty Chemicals: Contributed ₹18,180 million. This segment focuses on Pyridine and its derivatives, Fine Chemicals, and Custom Development and Manufacturing Operations (CDMO). It achieved an EBITDA of ₹4,220 million with margins reaching 25-26% in recent quarters.
    • Nutrition & Health Solutions: Contributed ₹7,473 million. Focuses on Vitamin B3, Vitamin B4 (Choline Chloride), and animal/human nutrition premixes. EBITDA for this segment stood at ₹1,018 million in FY 2025.
    • Chemical Intermediates: Contributed ₹16,123 million. This segment produces large-volume acetyl products like Acetic Anhydride and Ethyl Acetate. EBITDA was ₹1,076 million in FY 2025.
  • Geographical Reach: Exports accounted for 46% of consolidated revenue in FY 2025, up from 41% in the previous year. Sales to the US market grew by 52% YoY, while Europe and Japan recorded 16% growth. The company serves over 1,500 customers across 63 countries.
  • Financial Performance: For FY 2025, the company reported a consolidated EBITDA of ₹5,569 million, reflecting a 22% YoY increase. Profit After Tax (PAT) rose by 37% to ₹2,512 million, with a Basic EPS of ₹15.9. The company successfully reduced its net debt to ₹5,444 million as of December 2025, a 20% year-on-year reduction.
  • Innovation and Strategic Initiatives:
    • CDMO Pipeline: Secured two major agro-CDMO contracts and is progressing with 15 pharmaceutical and 8-10 semiconductor-focused molecules.
    • Capacity Expansion: Commissioned a new food and cosmetic-grade Niacinamide facility at Bharuch and a new Diketene-derivatives plant.
    • Cost Optimization: Achieved over ₹1,200 million in annual savings through its Phase 1 cost-reduction program and has targeted further savings of ₹1,000 million to ₹1,200 million for FY 2026.
    • Pinnacle 3.4.5: A long-term strategic vision aiming to triple revenue and quadruple EBITDA over a five-year horizon through a pivot toward high-value specialty and nutrition products.
  • Sustainability: The company is a Responsible Care certified entity and was recognized by the World Economic Forum in 2024 as part of the Global Lighthouse Network for its deployment of Fourth Industrial Revolution (4IR) technologies.

References

  1. Annual Report May 2025
  2. Investor Presentation Feb 2026
  3. Earnings Call Oct 2025
  4. Annual Report May 2024

Jubilant Ingrevia FAQ

Jubilant Ingrevia today is trading in the red, down by 1.66% at ₹558.4.
Jubilant Ingrevia is currently trading down 1.66% on an intraday basis. In the past week the stock fell 7.23%. Stock has been down 23.34% in the past quarter and fell 19.94% in the past year. You can view this in the share price history/seasonality section.
Jubilant Ingrevia is listed on NSE with the ticker JUBLINGREA and on BSE as 543271. It's currently trading on NSE at a share price of ₹558.4 and on BSE with a share price of ₹557.2.
The market cap of Jubilant Ingrevia is ₹8,894.26 Cr. as of Oct 30, 2026.
Jubilant Ingrevia announced a FINAL dividend of 250% which equals ₹2.5 in Jul 24, 2026.The last three ex-dates for Jubilant Ingrevia were Feb 10, 2026, Jul 25, 2025 and Feb 03, 2025. To view the full dividend history of Jubilant Ingrevia click here.
Jubilant Ingrevia has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Jubilant Ingrevia reported ₹1,403.26 Cr. in revenue, ₹111.43 Cr. in net profit, and ₹221.44 Cr. in EBITD as of Oct 27, 2026 for Q2 FY26-27.
According to the predictions of 6 analysts, the share price prediction for Jubilant Ingrevia is ₹905 with an upside of 62%.
The PE ratio of Jubilant Ingrevia is 25.37 as of Oct 30, 2026.
The PB ratio of Jubilant Ingrevia is 2.75 as of Oct 30, 2026.
You can view the latest analyst reports on the Jubilant Ingrevia reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×